Laurus Labs Posts Record Q1 FY27 Results

Revenue reached ₹2,026 crore, a 29% increase year-on-year.
Profit After Tax (PAT) stood at ₹368 crore.

Reader Takeaway: Strong CDMO growth and increased capex signal future expansion and demand. Watch execution and leverage.

What just happened

Laurus Labs announced its financial results for the first quarter of FY27. The company achieved record revenue of ₹2,026 crore, marking a significant 29% growth compared to the same period last year. Profit After Tax (PAT) was reported at ₹368 crore. The company's EBITDA stood at ₹644 crore with an improved EBITDA margin of 31.8%.

Why this matters

These results demonstrate robust performance across key business segments, particularly the CDMO (Contract Development and Manufacturing Organization) division, which saw a substantial 69% revenue increase to ₹835 crore. This growth is driven by late-stage clinical and commercial deliveries. The Affordable Medicines division also contributed with a 10% rise to ₹1,156 crore. The company's decision to double its FY27 capital expenditure guidance to ₹2,000 crore indicates strong confidence in future demand and strategic expansion plans.

The backstory

Laurus Labs has been focusing on diversifying its revenue streams beyond its traditional generics business, with a strategic emphasis on its CDMO and Biologics segments. The company has been investing in expanding its small molecule capacity and exploring new modalities. Regulatory compliance and quality audits have been a consistent focus, with the company highlighting its success in passing numerous audits without critical findings.

What changes now

The revised capital expenditure plan, now ₹2,000 crore for FY27, signifies a major push towards scaling up capacity for small molecules and new areas like peptides, Antibody-Drug Conjugates (ADCs), and gene therapy. This expanded investment is aimed at meeting growing customer demand. Laurus Bio also saw a 21% rise in sales, with new fermentation capacity expected soon.

Risks to watch

The increased capital expenditure, while positive for future growth, carries inherent risks. These include the gestation period for new capacities, potential impacts on short-term financial leverage, and the need to meet projected Return on Capital Employed (ROCE) targets. The company also continues to monitor global macroeconomic conditions and raw material costs for potential margin pressures.

Peer comparison

Laurus Labs operates in the pharmaceutical and contract research and manufacturing services (CRAMS) sector. Its peers include companies like Divi's Laboratories, PI Industries, and Syngene International, which also have significant CDMO and custom synthesis businesses. The performance of these companies is often benchmarked on revenue growth, EBITDA margins, and their ability to secure long-term manufacturing contracts.

Context metrics (time-bound)

• Revenue for Q1 FY27: ₹2,026 crore (up 29% YoY).
• CDMO Sales: ₹835 crore (up 69% YoY).
• Affordable Medicines Revenue: ₹1,156 crore (up 10% YoY).
• Laurus Bio Sales: ₹35 crore (up 21% YoY).
• EBITDA: ₹644 crore (Margin: 31.8%).
• Debt-to-EBITDA ratio: 1.28.
• FY27 Capex Guidance: Revised to ₹2,000 crore (previously undisclosed, but stated as doubled).

What to track next

Investors will be closely watching the execution of the expanded capital expenditure plan, the ramp-up in new high-value segments such as biologics and ADCs, and the company's ability to maintain its strong growth momentum and profitability amidst evolving market conditions. The company's success in managing its debt levels while undertaking significant expansion will also be crucial.